title: Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids.
abstract: The aim of this analysis was to assess changes in lipid parameters, specifically in triglyceride (TG) levels, in a population at ultra-high risk (UHR) for psychosis treated with ω-3 polyunsaturated fatty acids (PUFAs) versus placebo.
  
  
  
  Data were derived from a randomized, double-blind, placebo-controlled trial conducted at an early psychosis unit. Eighty-one individuals, aged 13-25 years, at UHR for psychosis participated in a 12-week intervention trial of 1.2 g/day of ω-3 PUFAs (n = 41) versus placebo (n = 40). Lipid and C-reactive protein levels were collected at baseline and after 12 weeks.
  
  
  
  Between-group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL-1there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω-3 group (n = 7).
  
  
  
  In this sample of UHR individuals, a 12-week intervention with ω-3 PUFAs was effective in reducing previously elevated TG levels. This might introduce the possibility of altering the lipid profile and thus the risk of cardiovascular morbidity of UHR individuals.
authors.affiliation: Department of Psychiatry and Psychotherapy, Clinical Division of Social Psychiatry, Medical University Vienna, Vienna, Austria.
authors.forename: Nilufar
authors.initials: N
authors.lastname: Mossaheb
authors.affiliation: Department of Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Vienna, Vienna, Austria.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Papageorgiou
authors.affiliation: Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria.
authors.forename: Miriam R
authors.initials: MR
authors.lastname: Schäfer
authors.affiliation: Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria.
authors.forename: Jana
authors.initials: J
authors.lastname: Becker
authors.affiliation: Department of Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Vienna, Vienna, Austria.|Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria.
authors.forename: Monika
authors.initials: M
authors.lastname: Schloegelhofer
authors.affiliation: Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria.|ORYGEN Research Centre, University of Melbourne, Melbourne, Victoria, Australia.
authors.forename: G Paul
authors.initials: GP
authors.lastname: Amminger
mesh_terms: D000293:Adolescent; D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D062706:Prodromal Symptoms; D011618:Psychotic Disorders / Q000097:blood* / Q000175:diagnosis / Q000178:diet therapy / Q000378:metabolism; D014280:Triglycerides / Q000097:blood*; D055815:Young Adult
chemical_list: D015525:Fatty Acids, Omega-3; D014280:Triglycerides; D002097:C-Reactive Protein
keywords: lipid; omega-3 fatty acid; psychosis; triglyceride; ultra-high risk